Document is current

Article History

Received: 4 March 2024

Accepted: 15 April 2024

First Online: 6 May 2024

Declarations

:

: This study was approved by the Alfred Health Human Research Ethics Committee (HREC: 87013), protocol date: 5 October 2022. This study used an ‘opt in’ approach, where it was implied that, by participating in the study, people were consenting to take part.

: EF and/or her institution reports grants from Brain Foundation (Australia); LivaNova (USA); Lundbeck (Australia); Monash Partners STAR Clinician Fellowship; Sylvia and Charles Viertel Charitable Foundation; The Royal Australian College of Physicians Fellows Research Establishment Fellowship.ZC was supported by the National Health and Medical Research Council of Australia Early Career Fellowship (GNT1156444) and has received grants from the Monash University. His institution has received research funding from UCB Pharma, outside the submitted work.CW is supported by an NHMRC Investigator Grant (APP2008300).ZA reports no disclosures relating to this study.EH reports no disclosures relating to this study. She has served on advisory boards for Sanofi-Genzyme, Novartis, Teva, Eli Lilly, Allergan and Lundbeck, and been involved in clinical trials sponsored by Novartis, Allergan, Lundbeck, Teva, Xalud, Cerecin, and has received payment for educational presentations from Allergan, Teva, Eli Lilly and Novartis. TJS is Director and Trustee of <i>Lifting The Burden</i>, a UK-registered non-governmental organization conducting the Global Campaign against Headache in official relations with the World Health Organization. He is associate editor of The Journal of Headache and Pain. He reports no other disclosures relating to this study.ASZ reports research grants from the Prince of Wales Hospital Foundation and from Lundbeck for the funding of this pilot study.